Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
23 hedge funds and large institutions have $623K invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.
4% less funds holding
Funds holding: 24 → 23 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
82% less capital invested
Capital invested by funds: $3.48M → $623K (-$2.86M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$8.1K |
| 2 |
CAC
Cowen and Company
New York
|
+$1.84K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
+$832 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
-$1.85K |
| 2 |
PCM
Prelude Capital Management
New York
|
-$1.5K |
| 3 |
AGM
Alpine Global Management
New York
|
-$186 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$148 |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$49 |
CLDI.WS Hedge Fund Activity: Q1 2023 in Review
23 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q1 2023, worth a combined $623K — down 82% from $3.48M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CLDI.WS and 1 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.
The largest buyer was Shaolin Capital Management, adding an estimated $8.1K. The largest seller was Parallax Volatility Advisers, cutting an estimated $1.85K.
- 23 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q1 2023, down from 24 in Q4 2022.
- Funds reported $623K of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q1 2023, down 82% quarter-over-quarter.
- 1 fund opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q1 2023 and 2 closed out, a net change of -1 holder.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q1 2023 was Shaolin Capital Management, an estimated $8.1K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q1 2023 was Parallax Volatility Advisers, an estimated $1.85K sold.
Based on aggregated 13F filings for Q1 2023.